Alvar, J and Arana, B (2018) I. Appraisal of leishmaniasis chemotherapy, current status and pipeline strategies. In Rivas, L, Gil, C (eds), Drug Discovery for Leishmaniasis. Cambridge, UK: Royal Society of Chemistry, pp. 1–23.
Alvar, J et al. (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clinical Microbiology Reviews 21, 334–359.
Alvar, J et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7, e35671.
Andrade-Neto, VV et al. (2011) The pharmacological inhibition of sterol biosynthesis in Leishmania is counteracted by enhancement of LDL endocytosis. Acta Tropica 119, 194–198.
Andrade-Neto, VV et al. (2016) Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole. Parasite & Vectors 9, 183.
Andre, P et al. (1998) An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proceedings of the National Academy of Sciences of the USA 95, 13120–13124.
Armitage, EG et al. (2018) A complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the Leishmania metabolome caused by miltefosine. Antimicrobial Agents and Chemotherapy. 62, e02095–17.
Arthington-Skaggs, BA et al. (1999) Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. Journal of Clinical Microbiology 37, 3332–3337.
Bastin, P et al. (1996) An M(r) 145,000 low-density lipoprotein (LDL)-binding protein is conserved throughout the Kinetoplastida order. Molecular and Biochemical Parasitology 76, 43–56.
Bitman, J and Wood, DL (1982) An improved copper reagent for quantitative densitometric thin-layer chromatography of lipids. Journal of Liquid Chromatography 5, 1155–1162.
Bligh, EG and Dyer, WJ (1959) A rapid method of total lipid extraction and purification. Canadian Journal of Biochemistry and Physiology 37, 911–917.
Chawla, B and Madhubala, R (2010) Drug targets in Leishmania. Journal of Parasitic Diseases 34, 1–13.
Coppens, I, Sinai, AP and Joiner, KA (2000) Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. Journal of Cell Biology 149, 167–180.
d'Avila, H, Toledo, DA and Melo, RC (2012) Lipid bodies: inflammatory organelles implicated in host-Trypanosoma cruzi interplay during innate immune responses. Mediators of Inflammation 2012, 478601.
Das, S et al. (2016) Na+ influx induced by new antimalarials causes rapid alterations in the cholesterol content and morphology of Plasmodium falciparum. PLoS Pathogens 12, e1005647.
Demarchi, IG et al. (2012) Effect of HIV protease inhibitors on New World Leishmania. Parasitology International 61, 538–544.
De Cicco, NN et al. (2012) LDL uptake by Leishmania amazonensis: involvement of membrane lipid microdomains. Experimental Parasitology 130, 330–340.
de Macedo-Silva, ST, de Souza, W and Rodrigues, JC (2015) Sterol biosynthesis pathway as an alternative for the anti-protozoan parasite chemotherapy. Current Medicinal Chemistry 22, 2186–2198.
de Souza, W and Rodrigues, JC (2009) Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdisciplinary Perspectives on Infectious Diseases 2009, 642502.
Ennes-Vidal, V et al. (2017) Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis? Parasitology 144, 117–123.
Farese, RV and Walther, TC (2009) Lipid droplets finally get a little R-E-S-P-E-C-T. Cell 139, 855–860.
Hruz, PW (2008) HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models. Current Opinion HIV and AIDS 3, 660–665.
Hui, DY (2003) Effects of HIV protease inhibitor therapy on lipid metabolism. Progress in Lipid Research 42, 81–92.
Lindoso, JA et al. (2016) Leishmaniasis-HIV coinfection: current challenges. HIV AIDS (Auckland, NZ) 8, 147–156.
Magaraci, F et al. (2003) Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. Journal of Medicine Chemistry 46, 4714–4727.
Mangold, HK (1969) Aliphatic lipids. In Stahl, E (ed.), Thin-Layer Chromatography. Berlin, Heidelberg: Springer, pp. 363–421.
Maxfield, FR and van Meer, G (2010) Cholesterol, the central lipid of mammalian cells. Current Opinion in Cell Biology 22, 422–429.
Murphy, DJ (2001) The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Progress in Lipid Research 40, 325–438.
Nolan, D (2003) Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63, 2555–2574.
Periard, D et al. (1999) Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700–705.
Perteguer, MJ et al. (2013) Ddi1-like protein from Leishmania major is an active aspartyl proteinase. Cell Stress and Chaperones 18, 171–181.
Rabhi, S et al. (2016) Lipid droplet formation, their localization and dynamics during Leishmania major macrophage infection. PLoS ONE 11, e0148640.
Rizza, SA and Badley, AD (2008) HIV protease inhibitors impact on apoptosis. Medicinal Chemistry 4, 75–79.
Rodrigues, JC et al. (2002) Ultrastructural and biochemical alterations induced by 22,26-azasterol, a delta(24(25))-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrobial Agents and Chemotherapy 46, 487–499.
Roingeard, P and Melo, RC (2017) Lipid droplet hijacking by intracellular pathogens. Cellular Microbiology 19, e12688.
Sangenito, LS et al. (2014) Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model. PLoS ONE 9, e113957.
Santos, ALS (2010) HIV aspartyl protease inhibitors as promising compounds against Candida albicans. World Journal of Biological Chemistry 1, 21–30.
Santos, ALS et al. (2017) EDITORIAL: old drugs x new perspectives/new compounds x old necessities: focusing on combating microbial resistance – part I. Current Topics in Medicinal Chemistry 17, 1117–1118.
Santos, LO et al. (2009) HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS ONE 4, e4918.
Santos, LO et al. (2013 a) Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients. Journal of Antimicrobial Chemotherapy 68, 348–353.
Santos, LO et al. (2013 b) Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy. Current Medicinal Chemistry 20, 3116–3133.
Savoia, D, Allice, T and Tovo, PA (2005) Antileishmanial activity of HIV protease inhibitors. International Journal of Antimicrobial Agents 26, 92–94.
Schmidtke, G et al. (1999) How an inhibitor of the HIV-I protease modulates proteasome activity. Journal of Biological Chemistry 274, 35734–35740.
Strober, W (2001) Trypan blue exclusion test of cell viability. Current Protocols in Immunology Appendix 3, Appendix 3B.
Sunpath, H et al. (2014) Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa. International Journal of Tuberculosis and Lung Diseases 18, 689–693.
Toledo, DA, D'Avila, H and Melo, RC (2016) Host lipid bodies as platforms for intracellular survival of protozoan parasites. Frontiers in Immunology 7, 174.
Trudel, N et al. (2008) Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. Journal of Infectious Diseases 198, 1292–1299.
Uliana, SR, Trinconi, CT and Coelho, AC (2017) Chemotherapy of leishmaniasis: present challenges. Parasitology 20, 1–17.
Valdivieso, E et al. (2010) Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Experimental Parasitology 126, 557–563.
van Griensven, J et al. (2013) HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. The Lancet Infectious Diseases 13, 251–259.
Vlahakis, SR et al. (2007) HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 12, 969–977.
White, RE, Powell, DJ and Berry, C (2011) HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites. FASEB Journal 25, 1729–1736.
Zha, BS et al. (2013) HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS ONE 8, e59514.